NVO logo

Novo Nordisk A/S (NVO) Accounts Receivable

Annual Accounts Receivable

$10.04 B
+$421.58 M+4.38%

December 31, 2024

Summary

Performance

1-Year Change

+4.38%

3-Year Change

+62.24%

5-Year Change

+168.77%

15-Year Change

+208.9%

NVO Accounts Receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

98.85%
NVO annual accounts receivable is higher than 98.85% of companies in Healthcare sector

High & Low

All-time High

$10.04 B
NVO annual accounts receivable is currently at an all-time high

3-Year Low

$6.19 B
NVO annual accounts receivable is currently +62.24% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2024
NVO previous annual earnings announcement was published on Dec 31, 2024

Next Annual Earnings Report Date

N/A
NVO next annual earnings announcement has not yet been scheduled

OtherNVObalance sheetmetrics:

Annual Accounts Payable

$4.02 B
NVO annual accounts payable is $4.02 billion

Annual Total Assets

$64.99 B
NVO annual total assets is $64.99 billion

Annual Total Liabilities

$44.97 B
NVO annual total liabilities is $44.97 billion

Annual Cash & Cash Equivalents

$2.18 B
NVO annual cash & cash equivalents is $2.18 billion

Quarterly Accounts Receivable

$10.04 B
+$107.71 M+1.08%

December 31, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+10.01%

3-Year Change

+62.24%

5-Year Change

+168.77%

NVO Quarterly Accounts Receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

98.71%
NVO quarterly accounts receivable is higher than 98.71% of companies in Healthcare sector

High & Low

All-time High

$10.04 B
NVO quarterly accounts receivable is currently at an all-time high

3-Year Low

$5.44 B
NVO quarterly accounts receivable is currently +84.58% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 31, 2024
NVO previous earnings announcement was published on Dec 31, 2024

Next Quarterly Earnings Report Date

N/A
NVO next earnings announcement has not yet been scheduled

OtherNVObalance sheetmetrics:

Quarterly Accounts Payable

$4.02 B
NVO quarterly accounts payable is $4.02 billion

Quarterly Total Assets

$64.99 B
NVO quarterly total assets is $64.99 billion

Quarterly Total Liabilities

$44.97 B
NVO quarterly total liabilities is $44.97 billion

Quarterly Cash And Cash Equivalents

$2.18 B
NVO quarterly cash and cash equivalents is $2.18 billion

Accounts Receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

NVO Accounts Receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+4.4%+10.0%
3 y3 years+62.2%+62.2%
5 y5 years+168.8%+168.8%

NVO Accounts Receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+62.2%at high+84.6%
5 y5-yearat high+168.8%at high+168.8%
alltimeall timeat high+2085.2%at high+2085.2%

Novo Nordisk A/S Accounts Receivable History

DateAnnualQuarterly
Dec 2024
$10.04 B(+4.4%)
$10.04 B(+1.1%)
Sep 2024
-
$9.93 B(+8.8%)
Jun 2024
-
$9.12 B(+10.7%)
Mar 2024
-
$8.25 B(-14.3%)
Dec 2023
$9.62 B(+32.1%)
$9.62 B(+29.1%)
Sep 2023
-
$7.45 B(-16.7%)
Jun 2023
-
$8.94 B(+21.0%)
Mar 2023
-
$7.39 B(+1.6%)
Dec 2022
$7.28 B(+17.6%)
$7.28 B(+20.8%)
Sep 2022
-
$6.02 B(+5.1%)
Jun 2022
-
$5.73 B(+5.4%)
Mar 2022
-
$5.44 B(-12.1%)
Dec 2021
$6.19 B(+35.0%)
$6.19 B(+32.8%)
Sep 2021
-
$4.66 B(+11.5%)
Jun 2021
-
$4.18 B(-5.5%)
Mar 2021
-
$4.42 B(-3.6%)
Dec 2020
$4.58 B(+22.7%)
$4.58 B(+19.4%)
Sep 2020
-
$3.84 B(-0.9%)
Jun 2020
-
$3.87 B(-12.8%)
Mar 2020
-
$4.44 B(+19.0%)
Dec 2019
$3.73 B(+7.0%)
$3.73 B(+13.2%)
Sep 2019
-
$3.30 B(-6.8%)
Jun 2019
-
$3.54 B(+9.7%)
Mar 2019
-
$3.23 B(-7.5%)
Dec 2018
$3.49 B(+7.4%)
$3.49 B(+21.0%)
Sep 2018
-
$2.88 B(-2.0%)
Jun 2018
-
$2.94 B(+8.9%)
Mar 2018
-
$2.70 B(-16.9%)
Dec 2017
$3.25 B(+12.9%)
$3.25 B(+19.4%)
Sep 2017
-
$2.72 B(+1.9%)
Jun 2017
-
$2.67 B(+9.3%)
Mar 2017
-
$2.44 B(-15.1%)
Dec 2016
$2.88 B(+26.9%)
$2.88 B(+17.8%)
Sep 2016
-
$2.44 B(+3.7%)
Jun 2016
-
$2.36 B(-6.1%)
Mar 2016
-
$2.51 B(+10.6%)
Dec 2015
$2.27 B(+6.5%)
$2.27 B(+10.9%)
Sep 2015
-
$2.05 B(-4.2%)
Jun 2015
-
$2.14 B(+0.6%)
Mar 2015
-
$2.12 B(-0.3%)
Dec 2014
$2.13 B(+5.5%)
$2.13 B(+15.5%)
Sep 2014
-
$1.84 B(-12.5%)
Jun 2014
-
$2.11 B(+9.2%)
Mar 2014
-
$1.93 B(-4.4%)
Dec 2013
$2.02 B
$2.02 B(+14.8%)
DateAnnualQuarterly
Sep 2013
-
$1.76 B(-8.4%)
Jun 2013
-
$1.92 B(+5.7%)
Mar 2013
-
$1.82 B(+6.4%)
Dec 2012
$1.71 B(+4.9%)
$1.71 B(+1.8%)
Sep 2012
-
$1.68 B(+1.0%)
Jun 2012
-
$1.66 B(-3.1%)
Mar 2012
-
$1.71 B(+5.2%)
Dec 2011
$1.63 B(+7.4%)
$1.63 B(-1.4%)
Sep 2011
-
$1.65 B(-9.7%)
Jun 2011
-
$1.83 B(+6.0%)
Mar 2011
-
$1.73 B(+13.9%)
Dec 2010
$1.52 B(+11.6%)
$1.52 B(-2.6%)
Sep 2010
-
$1.56 B(+9.5%)
Jun 2010
-
$1.42 B(-3.8%)
Mar 2010
-
$1.48 B(+8.7%)
Dec 2009
$1.36 B(+9.8%)
$1.36 B(+0.2%)
Sep 2009
-
$1.36 B(-0.8%)
Jun 2009
-
$1.37 B(+15.2%)
Mar 2009
-
$1.19 B(-4.1%)
Dec 2008
$1.24 B(+3.7%)
$1.24 B(-6.7%)
Sep 2008
-
$1.33 B(+0.7%)
Jun 2008
-
$1.32 B(+0.9%)
Mar 2008
-
$1.31 B(+9.5%)
Dec 2007
$1.19 B(+30.6%)
$1.19 B(+1.0%)
Sep 2007
-
$1.18 B(+7.5%)
Jun 2007
-
$1.10 B(+13.3%)
Mar 2007
-
$970.00 M(+6.2%)
Dec 2006
$913.47 M(+20.4%)
$913.47 M(+6.8%)
Sep 2006
-
$855.00 M(-1.3%)
Jun 2006
-
$866.27 M(+9.2%)
Mar 2006
-
$793.12 M(+4.5%)
Dec 2005
$759.00 M(+2.0%)
$759.00 M(-1.4%)
Sep 2005
-
$769.57 M(+1.5%)
Jun 2005
-
$757.91 M(+2.4%)
Mar 2005
-
$740.41 M(-0.5%)
Dec 2004
$744.27 M(+15.2%)
$744.27 M(+18.3%)
Sep 2004
-
$629.15 M(+0.1%)
Jun 2004
-
$628.31 M(+1.6%)
Mar 2004
-
$618.59 M(-4.2%)
Dec 2003
$646.02 M(+20.4%)
$646.02 M(+20.4%)
Dec 2002
$536.54 M(+16.8%)
$536.54 M(+16.8%)
Dec 2001
$459.38 M(-21.7%)
$459.38 M(-21.7%)
Dec 2000
$587.05 M(-20.7%)
$587.05 M(-20.7%)
Dec 1999
$740.38 M(-17.2%)
$740.38 M(-17.2%)
Dec 1998
$893.87 M
$893.87 M

FAQ

  • What is Novo Nordisk A/S annual accounts receivable?
  • What is the all time high annual accounts receivable for Novo Nordisk A/S?
  • What is Novo Nordisk A/S annual accounts receivable year-on-year change?
  • What is Novo Nordisk A/S quarterly accounts receivable?
  • What is the all time high quarterly accounts receivable for Novo Nordisk A/S?
  • What is Novo Nordisk A/S quarterly accounts receivable year-on-year change?

What is Novo Nordisk A/S annual accounts receivable?

The current annual accounts receivable of NVO is $10.04 B

What is the all time high annual accounts receivable for Novo Nordisk A/S?

Novo Nordisk A/S all-time high annual accounts receivable is $10.04 B

What is Novo Nordisk A/S annual accounts receivable year-on-year change?

Over the past year, NVO annual accounts receivable has changed by +$421.58 M (+4.38%)

What is Novo Nordisk A/S quarterly accounts receivable?

The current quarterly accounts receivable of NVO is $10.04 B

What is the all time high quarterly accounts receivable for Novo Nordisk A/S?

Novo Nordisk A/S all-time high quarterly accounts receivable is $10.04 B

What is Novo Nordisk A/S quarterly accounts receivable year-on-year change?

Over the past year, NVO quarterly accounts receivable has changed by +$913.23 M (+10.01%)